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Recent observations by Francis and Tillett (1) and by the present 
writers (2) have indicated that in patients ill with or recovering from 
lobar pneumonia the intracutaneous injection of small amounts of the 
protein-free  type-specific carbohydrate of  the  pneumococcus is  fol- 
lowed by the appearance of circulating antibodies specific for the type 
of carbohydrate injected.  These findings contrast with previous fail- 
ures to stimulate antibody production in animals with the same mate- 
rials  (3).  It  was,  therefore, of  interest  to determine whether such 
specific antibody response could be elicited in the absence of pneumo- 
coccic infection or by the use of other pneumococcus products. 
In the present investigation, human subjects without recent pneu- 
mococcic or other infections were studied with respect to their specific 
humoral antibody response to the intracutaneous injection of various 
pneumococcus products.  Type-specific  carbohydrates,  acetic  acid- 
precipitable proteins,  and  autolysates were used,  simultaneously in 
some subjects and separately in others.  The whole defibrinated blood 
of  the  subjects  was  studied  for  pneumococcidal  power  and  their 
serum tested for agglutinins and for passive protection in mice. 
The subjects chosen for the present study, the materials used for the intracuta- 
neous injections, and  the immunological methods  employed were,  in almost all 
respects,  identical with  those  described elsewhere  (4),  except  that  no  children 
under  15  years of  age  were  included.  Throughout  this  work  pneumococcidal 
power was said to be present only when more than 10 organisms were killed and 
* This study was aided, in part, by a  grant from the William W. Wellington 
Fund of the Harvard Medical School. 
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protection only when it was demonstrated against more than  10 lethal doses.  In- 
creases  or decreases  of less  than lO0-fold in these two properties were not con- 
sidered significant. 
Multiple  Simultaneous  Injections  of Various  Products  of Three  Types  of 
Pneumococci 
The first tests were done on 10 persons over 60 years of age.  Old individuals 
were chosen because of the well known high fatality of  lobar pneumonia among 
them and because of the finding of a somewhat lowered incidence of pneumococci- 
dal power in their blood (4).  Blood was taken for immunological studies and, 
subsequently, 16 intracutaneons injections were arranged on the flexor  surfaces 
of the forearms.  The solutions injected were in 0.1  co. amounts, containing the 
following substances:-- 
nag. S.S.S.  of Pneumococcus I 
"  "  "  "  II 
"  "  "  "  III 
"  nucleoprotein  "  Streptococcus scarlatinae 
0.01 
0.01 
0.01 
0.1 
0.01  "  "  "  "  " 
0.01  "  "  "  Pneumococcus  I  S 
0.01  "  "  "  "  I  R 
0.01  "  "  "  "  II S 
0.01  "  "  "  "  II R 
0.01  "  autolysate  "  "  I  S 
O. 1  "  "  "  "  I  S 
0.01  "  "  "  "  II S 
0.1  "  "  "  "  II S 
0.01  "  "  "  "  I  R 
O. 1  "  "  "  "  I  R 
Physiological saline 
Blood was again obtained for immunological  studies at various intervals after the 
intracutaneous injections. 
Antibodies appeared or an increase was demonstrated in previously 
existing antibodies in 9 of the 10 subjects.  The results of the immuno- 
logical tests performed on the whole blood and serum of 4  individuals, 
representing the various kinds of response, are shown in Table I. 
Some individuals who  had  a  high pneumococcidal titer before  the 
intracutaneous injections, later had either lowered or absent pneumo- 
coccidal  action for  some  pneumococcus types  against which  specific 
mouse-protective  antibodies and  agglutinins appeared  or  increased. 
This is illustrated in Subject L.  M.,  Table I.  Among these  10  sub- MAXWELL  FINLAND  AND  W.  D.  SUTLIFF  855 
jects there were 4 instances where mouse-protective antibodies against 
one type of pneumococcus were found before the intracutaneous inocu- 
lations.  The titer of protection against  this  type  in  later tests was 
the same in 2 of these subjects and was increased in the other 2  (see 
Table I, Subject M. B.) 
The aggregate results in the  10 persons  receiving multiple simul- 
taneous injections of several pneumococcus products are shown graph- 
TABLE  I 
Subject, age, and 
diagnosis 
M.  D.,  70  yrs., 
fractured hip 
M.  B.,  65  yrs., 
arteriosclerosis 
R.  R.,  60  yrs., 
hypertension 
L.  M.,  65  yrs., 
fractured femur 
Date of 
tests* 
Mar. 3 
"  19 
Apr.  3 
"  27 
[  Jan.  27 
I  Feb.  24 
[  Mar.  5 
I  "  13 
"  19 
]  "  4 
[  "  19 
* The intracutaneous in 
Pneumococcidal tlter 
(diplococcl killed) 
T?e 
0 
104 
106 
0 
0 
104 
103 
108 
I0  5 
104 
0 
Protection titer 
(lethal doses) 
o  o 
1~  108  0 
102  108  0 
10  0  0 
0  10  ~  0 
0  10  ~  104 
0  0  0 
102  10  ~  0 
102  10'  0 
0  0  10 
10  ~  1~  +  104+ 
Agglutinin  titer 
(serum dilution) 
0 
1:1 
1:2 
0 
0 
0 
0 
0 
0 
0 
1:8 
iections were done on the day of the first tests. 
ically in  Fig.  1.  A  study of this  figure shows that pneumococcidal 
power, mouse-protective  antibodies,  and agglutinins were more fre- 
quent following the intracutanoous injections than before.  This was 
true for each of the three pneumococcus types. 
The time of appearance or increase of the various antibodies and 
their duration were not accurately determined.  In general,  the in- 
crease appeared in  1 week and was demonstrable 1 month after the 
inoculations.  The only person in  this group on whom observations 
were made after more than 4 weeks (M. D., Table I) showed a loss of 
most of the newly demonstrated antibodies after about 8 weeks. 8~6  ANTIBODY  RESPONS]~  TO PNEUMOCOCCUS  PRODIYCTS 
It is thus seen that the simultaneous intradermal injection of many 
pneumococcus products  in  human  subjects  without  recent pneumo- 
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FIG. l.  Antibody response to the simultaneous  intradcrmal injection of several 
pneumococcus products. 
The solid portionsin Figs. 1 to 4 represent subjects with antibodies and the light 
portions  those without  antibodies.  Single  crosses  represent subjects in  whom 
previously existing antibodies could not be demonstrated after the intracutaneous 
injections.  The areas with ~ngle hoJchings  represent subjects in whom antibodies 
were diminished  and the cross-hc~ched portions subjects in whom antibodies were 
increased after the injections. 
coccic infection, was followed by the appearance or increase in anti- 
bodies for all three types of pneumococci.  In the experiments which MAXWELL  FINLAND  AND  W.  D.  SUTLIFF  857 
follow, the response of  such subjects was studied  after  injections of 
individual pneumococcus materials. 
Single and Repeated Injections of Type-Specific Polysaccharide 
A single intracutaneous injection of 0.01 rag. of the protein-free type-specific 
carbohydrate was given to 19 individuals (Type I, 7 cases; Type II, 6; and Type 
III, 6) and similar injections on 4 successive  days were given to 10 others (Type I, 
3 cases; Type II, 3; and Type III, 4).  The subjects ranged in age from 15 to 56 
years.  Antibodies for all three types were studied in each subject before and at 
intervals after the intracutaneous injections.  Inasmuch  as no apparent  differ- 
ences were observed between the results of the single and of the 4 daily injections, 
they are considered together. 
The results obtained with each of the polysaccharides were similar. 
Among the 29 subjects,  11 had pneumococcidal power for the homol- 
ogous type of pneumococcus before the injection.  12 of the 18 per- 
sons having no demonstrable pneumococcidal action for the type cor- 
responding to the polysaccharide injected showed, in subsequent tests, 
pneumococcidal power  for  the  homologous  type  of  pneumococcus, 
either alone or along with mouse protection or agglutination for the 
same type.  Of the 11 persons having pneumococcidal power for the 
homologous organism before the intracutaneous injection,  8  showed 
diminished or unchanged titer for this organism along with the appear- 
ance or increase in the serum of mouse-protective antibodies or agglu- 
tinins, or both.  In 9 persons no change was demonstrated; 3 of these 
had pneumococcidal power in  their blood before the intracutaneous 
injections.  The homologous pneumococcidal titer acquired was usu- 
ally moderate, 0.5 cc. of blood acquiring the capacity to kill 1000 diplo- 
cocci in 2 instances, 10,000 in 8, and 100,000 in 2. 
Mouse  protection  was  acquired  against  100  lethal  doses  of  the 
homologous organism in 7 subjects, against 1000 lethal doses in 5, and 
against 100,000 lethal doses in 2.  Agglutinins were found in 10 indi- 
viduals in final dilutions of 1:4 or 1:8 of the serum. 
Heterologous antibodies did not, as a rule, appear following the injec- 
tion of one of the polysaccharides.  In several subjects pneumococci- 
dal power,  that  had been present for heterologous types before the 
inoculations, was significantly lower or entirely absent after the intra- 
cutaneous injection.  Unlike the lowering of pneumococcidal power 858  ANTIBODY RESPONSE TO PNEUMOCOCCUS  PRODUCTS 
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Fie. 2.  Antibody response to the intracutaneous injection of the purified type- 
specific polysaccharides of Type I, II, or III pneumococci. MAXWELL  FINLAND  AND  W.  D.  SUTLIFF  859 
for the homologous type, this was not  associated with  the  appear- 
ance  of  protective  antibodies or agglutinins.  In isolated instances, 
heterologous antibodies were demonstrated following the injections of 
one of the specific carbohydrates.  Pneumococcidal power for Type 
I  was demonstrated in 1 instance after the injection of Type II S.S.S. 
Agglutinins for Type III pneumococci were found in 1 person after he 
had received Type I  S.S.S.  This person, however, had high Type III 
pneumococcidal and mouse protection titers before the injection of the 
Type I  material.  In 2 instances there was a  definite increase in the 
protection titer against Type III pneumococci after Type I and Type 
II S.S.S. respectively had been given. 
The  cases  showing significant changes in their circulating homol- 
ogous and heterologous antibodies following intracutaneous injections 
of one of the type-specific polysaccharides are  shown graphically in 
Fig. 2. 
The specific antibodies were demonstrated in almost every instance 
from 7 to 10 days after the intracutaneous inoculations.  They were 
again found throughout the period of observation which was about 3 
weeks in most cases.  In a single instance, homologous  protective anti- 
bodies and agglutinins acquired following an injection of Type II S.S.S. 
were demonstrated after 2 months. 
These observations, therefore, show that a single intracutaneous in- 
jection of 0.01 nag. of the specific polysaccharide of Type I, Type II, 
or Type III pneumococci or 4 similar daily injections may be followed 
by the appearance of pneumococcidal power, mouse protection, and 
agglutinins for the homologous organism in human adults whose blood 
previously  lacked  these properties.  In  subjects  originally  having 
pneumococcidal power there may be a decrease in this power with a 
simultaneous appearance of protective antibodies and agglutinins for 
the  same  organism.  The  pneumococcidal power  for  heterologous 
types of pneumococci may be depressed in some individuals without 
changes in the mouse-protective or agglutinating properties for these 
types.  Heterologous antibodies are  not  usually acquired  following 
the intracutaneous injection of the type-specific polysaccharides. 
Single Injections of Pneumococcus Nucleoprotei~ 
13 subjects were given a single intracutaneous injection of 0.1 rag. of nucleo- 
protein and their humoral antibodies were studied before and at intervals up to 5 860  ANTIBODY  ILESPONSE  TO PNE~OCOCCUS  PRODUCTS 
weeks after this injection.  The proteins used in 7 instances were obtained from 
highly virulent strains of Type I  (5 cases) and Type II (2 cases) pneumococci. 
Those  used in  the  remaining  subjects  were  derived from degraded,  avirulent 
strains obtained from Type I  (4 cases) and Type II  (2 cases) organisms.  No 
significant differences were observed in the response to the various proteins used, 
and the results are considered collectively. 
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Fzc. 3. Antibody response to single intracutaneous injection of pneumococcus 
protein. 
The results of the antibody studies in the 13 subjects are summarized 
graphically in Fig.  3.  A  study of this figure shows that no uniform 
changes  were  exhibited  in  this  group  of  individuals  following  the 
protein  injections.  4  persons  apparently  acquired  pneumococcidal MAXWELl.  ~'INLAND  AND  W.  D.  SUTl.IFF  861 
power, but this was only of low titer; whereas, lowering or loss of pneu- 
mococcidal power was more often encountered.  Agglutinins were ir- 
regular.  Mouse-protective antibodies did not develop. 
From the findings in this small group of subjects, therefore, it ap- 
pears that no definite or constant changes in the humoral type-specific 
antibodies follow a single intracutaneous injection of 0.1 rag. of pneu- 
mococcus nucleoprotein.  This  is  in  accord  with previous  observa- 
tions in animals by Avery. and Morgan (3). 
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FIG. 4. Antibody  response to single intracutaneous injection of autolysate of 
virulent strains of Type I, II, or III pneumococci. 
Single Injections of Pneumococcus A utolysate 
The antibody response to a single intracutaneous injection of small amounts of 
autolysates prepared from highly virulent strains of Type I, II, or III pneumococci 
was studied in 11 individuals, ranging from 17 to 50 years of age.  The Type I 
autolysate was given to 3 subjects and the Type II and Type III autolysates were 
each given to 4 subjects.  The quantity injected ineach instance contained 0.1 
mg. of protein.  The responses to the autolysates of the various types were uniform 
and are considered together. 
There was a general increase in pneumococcidal power for both the 
homologous and heterologous types of pneumococci in most instances. 
Mouse-protective antibodies (against 1000 lethal doses in 2 subjects, 862  ANTIBODY  RESPONSE  TO  PNEUMOCOCCUS  PRODUCTS 
10,000 in 1, and 100,000 in another) and agglutinins (in 1:4 dilutions 
of sera), however, appeared for the homologous organism only.  Type 
I  pneumococcidal power appeared in only 2  of the 8  subjects  that 
received Type II or Type III autolysate, whereas Type II and Type 
III pneumococcidal power appeared or increased in all of the subjects 
without respect to the type of autolysate injected.  The results of 
these findings are summarized graphically in Fig. 4. 
A single injection of a  small amount of autolysate derived from a 
virulent strain of either Type I, Type II, or  Type  III pneumococci 
was, thus, followed in most of the subjects studied, by an appearance 
or increase in the pneumococcidal power of the blood for all  three 
types.  Mouse-protective  antibodies  and  agglutinins,  however,  ap- 
peared for the homologous types only. 
DISCUSSION 
In the first group of subjects various products of virulent strains of 
pneumococci,  including  their  type-specific  carbohydrates,  were  in- 
jected simultaneously.  Following these injections there was a general 
rise in the circulating antibodies for the types of pneumococci from 
which these products were derived.  This is not in agreement with the 
findings of Julianelle (5), who failed to demonstrate, in rabbits, a type- 
specific response to the intracutaneous injection of materials derived 
from Type I pneumococci. 
The findings in the other groups of subjects suggest that the intra- 
dermal injection in normal human adults of a protein-free, type-spe- 
cific carbohydrate, prepared according to the methods of Heidelberger, 
Goebel, and Avery (6), is frequently followed by the appearance in the 
circulating blood of antibodies specific for the type of pneumococcus 
from which the carbohydrate was derived.  Heterologous antibodies 
could not be demonstrated.  It would thus appear that the carbohy- 
drate was responsible for the type-specific response that followed the 
simultaneous injection of a variety of pneumococcus products.  Fur- 
thermore, the circulating antibodies to  heterologous types  of pneu- 
mococci  demonstrated,  following  intracutaneous  test  injections  of 
carbohydrate, in cases recovering from lobar pneumonia (1, 2) need not 
be considered dependent on processes associated with recovery from 
the pneumococcic infection.  They would appear  rather  to  be  the MAXWELL  FINLAND  AND  W.  D.  SUTLIFF  863 
usual reaction of at least a large percentage of normal human adults 
following such injections. 
It is necessary to emphasize that the studies here presented refer, 
primarily, to the results of single intracutaneous injections of small 
doses.  The findings of Schiemann and Caspar (7) suggest that dosage 
may be  an important factor.  These workers demonstrated specific 
protection  in  mice  following the  intraperitoneal  injection of  small 
amounts of  their  soluble  protein-free,  specifically precipitable  sub- 
stance, whereas, an increase of 100-fold in the dose of the same mate- 
rial failed to stimulate such immunity. 
It would appear from the present data that 4 daffy injections of the 
same amount of the polysaccharide do not materiallyalter the response. 
From the results, however, in pneumonic patients reported elsewhere 
(2), it would appear that repeated skin tests with polysaccharides at 
longer intervals may result in the maintenance of a fairly high degree of 
specific immunity for long periods, for 2 of the pneumonic subjects who 
received repeated injections were shown to have antibodies at the end 
of 13 and 14 months after the polysaccharide injections were begun. 
In the case of the pneumococcidal power of the whole defibrinated 
blood, the response to the intracutaneously injected polysaccharides 
was different in  those subjects originally possessing or lacking this 
power.  Among the  former  a  significant  percentage  acquired  this 
power with respect to the homologous type after the injections.  This 
property was not, however, demonstrated for a type of pneumococcus 
heterologous to that of the polysaccharide injected.  In the subjects 
originally  having pneumococcidal power,  the  intracutaneous  injec- 
tions were frequently followed by a decrease in titer or even complete 
loss of pneumococcldal power for both the homologous and heterolo- 
gous types.  This decrease was accompanied by the appearance, in the 
serum, of mouse-protective antibodies or agglutinins for the homologous 
type.  No such antibodies appeared for the heterologous types.  The 
explanation of these phenomena is not entirely clear and may depend 
on a more exact understanding of the factors involved in the pneumo- 
coccidal test. 
The specific humoral response to  single injections of acetic acid- 
precipitable proteins derived from virulent and avirulent pneumococci 
was quite irregular and can hardly be considered significant.  On the 8~  ANTIBODY  I~ESPONSE  TO  PNEUMOCOCCUS  PRODUCTS 
other hand, the  antibody response  to  the  autolysate used in  these 
experiments was distinctly different from that obtained with the puri- 
fied carbohydrates or with the nucleoprotein solutions.  The autoly- 
sate of each of three types of virulent pneumococci used gave a general 
rise  in  pneumococcidal power for  all  three  types but  such specific 
agglutinins  and  mouse-protective antibodies as  were  demonstrated 
appeared only for the homologous type organism.  No lowering of the 
pneumococcidal titer  was observed in  this group.  The  number of 
subjects  studied  was,  however, small  and none originally  had  any 
high degree of pneumococcidal  power. 
S~YMMARY 
The blood of 63 human subjects selected because of the absence of 
recent infections, was  studied for its  content of specific antibodies 
against virulent strains of Types I, II, and III pneumococci before and 
after intracutaneous injections of minute amounts of pneumococcus 
products. 
The  simultaneous injection of  the  specific polysaccharides of all 
three types of pneumococci and of proteins and autolysates derived 
from Types I and II pneumococci was followed by the appearance or 
increase of pneumococcidal  power in the whole defibrinated blood and, 
in most instances, by the appearance of mouse-protective antibodies 
and agglutinlns for one or more types. 
A  single intracutaneous injection of 0.01  mg.  of the protein-free 
type-specific polysaccharide of either Type I,  Type II, or Type III 
pneumococci or 4 similar daily injections was followed, in most of 29 
subjects, by the appearance of antibodies against the homologous, but 
not  against  the  heterologous  type  pneumococci.  Some  subjects 
showed a simultaneous lowering of a preexisting pneumococcidal  power 
for heterologous or homologous types. 
A single intracutaneous injection of 0.1 rag. of pneumococcus  protein 
in 13 individuals was not followed by the appearance of specific anti- 
bodies to any appreciable degree. 
Single intracutaneous injections of small amounts of  autolysates 
derived from virulent strains of Type I, II, or III pneumococci were 
followed in 11 subjects by a more or less general rise in the pneumococ- MAXWELL  ~'I!~AND AND  W. D.  SUTLIFF  865 
cidal power with the appearance of homologous type agglutinins and 
protective antibodies in about one-third of the subjects. 
The authors gratefully acknowledge the technical assistance of Miss 
Beatrice Tyndall. 
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